Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) Stock Competitors & Peer Comparison
See DMII's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Financial - Conglomerates Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for DMII and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| DMII | $10.17 | -0.05% | 648.5M | 72.71 | $0.14 | N/A |
| FRHC | $164.48 | -0.14% | 10.1B | 65.53 | $2.51 | N/A |
| BIPH | $15.50 | -0.32% | 5.7B | N/A | N/A | +8.15% |
| HTH | $38.65 | +0.00% | 2.2B | 14.63 | $2.64 | +2.08% |
| MSDL | $14.63 | -1.68% | 1.2B | 7.46 | $1.96 | +12.98% |
| RILYK | $25.23 | +0.16% | 787.6M | N/A | N/A | N/A |
| RILYM | $25.11 | +0.00% | 753M | N/A | N/A | N/A |
| TMS | $8.13 | +9.86% | 585.2M | N/A | N/A | N/A |
| RILYO | $25.13 | -0.02% | 573.5M | N/A | N/A | N/A |
| CCXIU | $12.73 | -5.70% | 546.4M | N/A | N/A | N/A |
Stock Comparison
Freedom Holding Corp. (NASDAQ: FRHC)
DMII vs FRHC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, FRHC has a market cap of 10.1B. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while FRHC trades at $164.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas FRHC's P/E ratio is 65.53. In terms of profitability, DMII's ROE is +0.03%, compared to FRHC's ROE of +0.11%. Regarding short-term risk, DMII is less volatile compared to FRHC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check FRHC's competition here
Brookfield Infrastructure Finance ULC 5 % Notes 2021-24.05.81 Global (NYSE: BIPH)
DMII vs BIPH Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, BIPH has a market cap of 5.7B. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while BIPH trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas BIPH's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BIPH's ROE of +0.06%. Regarding short-term risk, DMII is less volatile compared to BIPH. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BIPH's competition here
Hilltop Holdings Inc. (NYSE: HTH)
DMII vs HTH Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, HTH has a market cap of 2.2B. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while HTH trades at $38.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas HTH's P/E ratio is 14.63. In terms of profitability, DMII's ROE is +0.03%, compared to HTH's ROE of +0.07%. Regarding short-term risk, DMII is less volatile compared to HTH. This indicates lower risk in terms of short-term price fluctuations for DMII.Check HTH's competition here
Morgan Stanley Direct Lending Fund (NYSE: MSDL)
DMII vs MSDL Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, MSDL has a market cap of 1.2B. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while MSDL trades at $14.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas MSDL's P/E ratio is 7.46. In terms of profitability, DMII's ROE is +0.03%, compared to MSDL's ROE of +0.03%. Regarding short-term risk, DMII is less volatile compared to MSDL. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MSDL's competition here
B. Riley Financial, Inc. 5.50% Senior Notes Due 2026 (NASDAQ: RILYK)
DMII vs RILYK Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYK has a market cap of 787.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYK trades at $25.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYK's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYK's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYK. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYK's competition here
B. Riley Financial, Inc. - 6.37 (NASDAQ: RILYM)
DMII vs RILYM Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYM has a market cap of 753M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYM trades at $25.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYM's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYM's ROE of -7.75%. Regarding short-term risk, DMII is more volatile compared to RILYM. This indicates higher risk in terms of short-term price fluctuations for DMII.Check RILYM's competition here
Teamshares Inc. (NASDAQ: TMS)
DMII vs TMS Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, TMS has a market cap of 585.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while TMS trades at $8.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas TMS's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TMS's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to TMS. This indicates lower risk in terms of short-term price fluctuations for DMII.Check TMS's competition here
B. Riley Financial, Inc. - 6.75 (NASDAQ: RILYO)
DMII vs RILYO Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYO has a market cap of 573.5M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYO trades at $25.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYO's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RILYO's ROE of -7.75%. Regarding short-term risk, DMII is more volatile compared to RILYO. This indicates higher risk in terms of short-term price fluctuations for DMII.Check RILYO's competition here
Churchill Capital Corp XI Units (NASDAQ: CCXIU)
DMII vs CCXIU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, CCXIU has a market cap of 546.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while CCXIU trades at $12.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas CCXIU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CCXIU's ROE of -0.59%. Regarding short-term risk, DMII is less volatile compared to CCXIU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CCXIU's competition here
Voyager Acquisition Corp. (NASDAQ: VACHU)
DMII vs VACHU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, VACHU has a market cap of 475.5M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while VACHU trades at $14.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas VACHU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VACHU's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to VACHU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VACHU's competition here
Legato Merger Corp. III (AMEX: LEGT-UN)
DMII vs LEGT-UN Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, LEGT-UN has a market cap of 467.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while LEGT-UN trades at $18.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas LEGT-UN's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LEGT-UN's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to LEGT-UN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LEGT-UN's competition here
Ares Acquisition Corp. III Class A (NYSE: AAC)
DMII vs AAC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, AAC has a market cap of 397.8M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while AAC trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas AAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to AAC's ROE of +6.83%. Regarding short-term risk, DMII is less volatile compared to AAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check AAC's competition here
Gores Holdings XI, Inc. Class A Ordinary Shares (NASDAQ: GHXI)
DMII vs GHXI Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, GHXI has a market cap of 363.9M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while GHXI trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas GHXI's P/E ratio is -7753.85. In terms of profitability, DMII's ROE is +0.03%, compared to GHXI's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to GHXI. This indicates higher risk in terms of short-term price fluctuations for DMII.Check GHXI's competition here
Cantor Equity Partners II, Inc. (NASDAQ: CEPT)
DMII vs CEPT Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, CEPT has a market cap of 360.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while CEPT trades at $11.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas CEPT's P/E ratio is -107.09. In terms of profitability, DMII's ROE is +0.03%, compared to CEPT's ROE of +0.01%. Regarding short-term risk, DMII is less volatile compared to CEPT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CEPT's competition here
RRE Ventures Acquisition Corp. (NASDAQ: RREV)
DMII vs RREV Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RREV has a market cap of 330.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RREV trades at $9.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RREV's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RREV's ROE of -31.07%. Regarding short-term risk, DMII is more volatile compared to RREV. This indicates higher risk in terms of short-term price fluctuations for DMII.Check RREV's competition here
B&R Technology Merger Corp. Class A (NASDAQ: BRTM)
DMII vs BRTM Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, BRTM has a market cap of 325.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while BRTM trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas BRTM's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BRTM's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to BRTM. This indicates lower risk in terms of short-term price fluctuations for DMII.Check BRTM's competition here
Safeguard Acquisition Corp. (NYSE: SAC)
DMII vs SAC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, SAC has a market cap of 316.5M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while SAC trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas SAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SAC's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to SAC. This indicates similar risk in terms of short-term price fluctuations for DMII.Check SAC's competition here
Velos Acquisition I Corp. Units Cons of 1 Sh + 1/2 Red Wt (NASDAQ: VLOSU)
DMII vs VLOSU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, VLOSU has a market cap of 316M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while VLOSU trades at $10.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas VLOSU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VLOSU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to VLOSU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check VLOSU's competition here
B. Riley Financial, Inc. 5.00% Senior Notes due 2026 (NASDAQ: RILYG)
DMII vs RILYG Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYG has a market cap of 311.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYG trades at $24.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYG's P/E ratio is -3.80. In terms of profitability, DMII's ROE is +0.03%, compared to RILYG's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYG. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYG's competition here
Velos Acquisition I Corp. (NASDAQ: VLOS)
DMII vs VLOS Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, VLOS has a market cap of 308.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while VLOS trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas VLOS's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VLOS's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to VLOS. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VLOS's competition here
Osprey Acquisition Corp. III (NASDAQ: OSPRU)
DMII vs OSPRU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, OSPRU has a market cap of 307.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while OSPRU trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas OSPRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OSPRU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OSPRU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OSPRU's competition here
BRC Group Holdings Inc. 5.25% Sr. Notes due 2028 (NASDAQ: RILYZ)
DMII vs RILYZ Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYZ has a market cap of 297.7M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYZ trades at $19.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYZ's P/E ratio is 3.99. In terms of profitability, DMII's ROE is +0.03%, compared to RILYZ's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYZ. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYZ's competition here
BRC Group Holdings, Inc. 6.50% Senior Notes Due 2026 (NASDAQ: RILYN)
DMII vs RILYN Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYN has a market cap of 295.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYN trades at $25.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYN's P/E ratio is 1.40. In terms of profitability, DMII's ROE is +0.03%, compared to RILYN's ROE of -7.75%. Regarding short-term risk, DMII is more volatile compared to RILYN. This indicates higher risk in terms of short-term price fluctuations for DMII.Check RILYN's competition here
B. Riley Financial, Inc. 6.00% Senior Notes Due 2028 (NASDAQ: RILYT)
DMII vs RILYT Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYT has a market cap of 294.1M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYT trades at $20.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYT's P/E ratio is 2.82. In terms of profitability, DMII's ROE is +0.03%, compared to RILYT's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYT's competition here
BRC Group Holdings, Inc. (NASDAQ: RILYP)
DMII vs RILYP Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYP has a market cap of 281.1M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYP trades at $12.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYP's P/E ratio is 0.86. In terms of profitability, DMII's ROE is +0.03%, compared to RILYP's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYP. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYP's competition here
NewHold Investment Corp IV Class A Ordinary Shares (NASDAQ: NHIV)
DMII vs NHIV Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, NHIV has a market cap of 276.1M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while NHIV trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas NHIV's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NHIV's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to NHIV. This indicates lower risk in terms of short-term price fluctuations for DMII.Check NHIV's competition here
BRC Group Holdings, Inc. - Depositary Shares, each representing a 1/1000th fractional interest in a share of Series B Cumulative Perpetual Preferred Stock (NASDAQ: RILYL)
DMII vs RILYL Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILYL has a market cap of 273.9M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILYL trades at $12.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILYL's P/E ratio is 0.86. In terms of profitability, DMII's ROE is +0.03%, compared to RILYL's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILYL. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILYL's competition here
DeFi Development Corp. (NASDAQ: CHAD)
DMII vs CHAD Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, CHAD has a market cap of 272.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while CHAD trades at $8.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas CHAD's P/E ratio is -1.27. In terms of profitability, DMII's ROE is +0.03%, compared to CHAD's ROE of +0.00%. Regarding short-term risk, DMII is less volatile compared to CHAD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CHAD's competition here
Mountain Lake Acquisition Corp. II Class A Ordinary Shares (NASDAQ: MLAA)
DMII vs MLAA Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, MLAA has a market cap of 262.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while MLAA trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas MLAA's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MLAA's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to MLAA. This indicates higher risk in terms of short-term price fluctuations for DMII.Check MLAA's competition here
AMR Resources Acquisition Corp Class A Ordinary Shares (NASDAQ: AMAC)
DMII vs AMAC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, AMAC has a market cap of 262.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while AMAC trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas AMAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to AMAC's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to AMAC. This indicates lower risk in terms of short-term price fluctuations for DMII.Check AMAC's competition here
Art Technology Acquisition Corp. (NASDAQ: ARTC)
DMII vs ARTC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, ARTC has a market cap of 260.5M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while ARTC trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas ARTC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ARTC's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to ARTC. This indicates similar risk in terms of short-term price fluctuations for DMII.Check ARTC's competition here
Columbus Circle Capital Corp II Units Cons of 1 Shs A + 1/3 Red Wt (NASDAQ: IPXGU)
DMII vs IPXGU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, IPXGU has a market cap of 259.1M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while IPXGU trades at $10.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas IPXGU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to IPXGU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to IPXGU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check IPXGU's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDBU)
DMII vs DRDBU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, DRDBU has a market cap of 254.1M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while DRDBU trades at $11.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas DRDBU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to DRDBU's ROE of +0.02%. Regarding short-term risk, DMII is more volatile compared to DRDBU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check DRDBU's competition here
Keystone Acquisition Corp. Unit (NASDAQ: KEYYU)
DMII vs KEYYU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, KEYYU has a market cap of 253.8M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while KEYYU trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas KEYYU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to KEYYU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to KEYYU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check KEYYU's competition here
OneIM Acquisition Corp. Warrant (NASDAQ: OIMAW)
DMII vs OIMAW Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, OIMAW has a market cap of 250M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while OIMAW trades at $0.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas OIMAW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OIMAW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OIMAW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OIMAW's competition here
Legato Merger Corp. III (AMEX: LEGT)
DMII vs LEGT Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, LEGT has a market cap of 247.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while LEGT trades at $9.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas LEGT's P/E ratio is 72.34. In terms of profitability, DMII's ROE is +0.03%, compared to LEGT's ROE of +0.04%. Regarding short-term risk, DMII is less volatile compared to LEGT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LEGT's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDB)
DMII vs DRDB Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, DRDB has a market cap of 245.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while DRDB trades at $10.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas DRDB's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to DRDB's ROE of +0.02%. Regarding short-term risk, DMII is more volatile compared to DRDB. This indicates higher risk in terms of short-term price fluctuations for DMII.Check DRDB's competition here
BRC Group Holdings, Inc. (NASDAQ: RILY)
DMII vs RILY Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RILY has a market cap of 240.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RILY trades at $5.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RILY's P/E ratio is 0.47. In terms of profitability, DMII's ROE is +0.03%, compared to RILY's ROE of -7.75%. Regarding short-term risk, DMII is less volatile compared to RILY. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RILY's competition here
Space Asset Acquisition Corp. Class A Ordinary Shares (NASDAQ: SAAQ)
DMII vs SAAQ Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, SAAQ has a market cap of 238.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while SAAQ trades at $10.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas SAAQ's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SAAQ's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to SAAQ. This indicates similar risk in terms of short-term price fluctuations for DMII.Check SAAQ's competition here
Inflection Point Acquisition Corp. VII (NASDAQ: IPXG)
DMII vs IPXG Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, IPXG has a market cap of 238.1M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while IPXG trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas IPXG's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to IPXG's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to IPXG. This indicates similar risk in terms of short-term price fluctuations for DMII.Check IPXG's competition here
Quantum Leap Acquisition Corp (NYSE: QLEP)
DMII vs QLEP Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, QLEP has a market cap of 237.7M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while QLEP trades at $10.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas QLEP's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to QLEP's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to QLEP. This indicates higher risk in terms of short-term price fluctuations for DMII.Check QLEP's competition here
Illumination Acquisition Corp I Class A Ordinary Shares (NASDAQ: ILLU)
DMII vs ILLU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, ILLU has a market cap of 235.8M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while ILLU trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas ILLU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ILLU's ROE of +0.00%. Regarding short-term risk, DMII is less volatile compared to ILLU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ILLU's competition here
Illumination Acquisition Corp I (NASDAQ: ILLUU)
DMII vs ILLUU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, ILLUU has a market cap of 234.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while ILLUU trades at $10.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas ILLUU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ILLUU's ROE of +0.00%. Regarding short-term risk, DMII is more volatile compared to ILLUU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check ILLUU's competition here
Bluerock Acquisition Corp. Class A Ordinary Shares (NASDAQ: BLRK)
DMII vs BLRK Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, BLRK has a market cap of 232.8M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while BLRK trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas BLRK's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BLRK's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to BLRK. This indicates similar risk in terms of short-term price fluctuations for DMII.Check BLRK's competition here
Metals Acquisition Corp (NYSE: MTAL-WT)
DMII vs MTAL-WT Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, MTAL-WT has a market cap of 230.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while MTAL-WT trades at $1.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas MTAL-WT's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MTAL-WT's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to MTAL-WT. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MTAL-WT's competition here
Viking Acquisition Corp. II (NYSE: VII)
DMII vs VII Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, VII has a market cap of 228.9M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while VII trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas VII's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VII's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to VII. This indicates similar risk in terms of short-term price fluctuations for DMII.Check VII's competition here
Yorkville International Capital Corp. (NASDAQ: YICC)
DMII vs YICC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, YICC has a market cap of 228.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while YICC trades at $9.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas YICC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to YICC's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to YICC. This indicates higher risk in terms of short-term price fluctuations for DMII.Check YICC's competition here
Oceanhawk Acquisition Corp. Rights (NASDAQ: OHACR)
DMII vs OHACR Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, OHACR has a market cap of 224M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while OHACR trades at $0.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas OHACR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OHACR's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to OHACR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check OHACR's competition here
Hall Chadwick Acquisition Corp. (NASDAQ: HCAC)
DMII vs HCAC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, HCAC has a market cap of 215.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while HCAC trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas HCAC's P/E ratio is 369.96. In terms of profitability, DMII's ROE is +0.03%, compared to HCAC's ROE of -0.68%. Regarding short-term risk, DMII is more volatile compared to HCAC. This indicates higher risk in terms of short-term price fluctuations for DMII.Check HCAC's competition here
RMG ML Sports Holdings (NASDAQ: SHOT)
DMII vs SHOT Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, SHOT has a market cap of 213.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while SHOT trades at $9.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas SHOT's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SHOT's ROE of +0.00%. Regarding short-term risk, DMII is similarly volatile compared to SHOT. This indicates similar risk in terms of short-term price fluctuations for DMII.Check SHOT's competition here
NewHold Investment Corp IV (NASDAQ: NHIVU)
DMII vs NHIVU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, NHIVU has a market cap of 212.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while NHIVU trades at $10.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas NHIVU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NHIVU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to NHIVU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check NHIVU's competition here
Vendome Acquisition Corporation I Warrant (NASDAQ: VNMEW)
DMII vs VNMEW Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, VNMEW has a market cap of 212.5M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while VNMEW trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas VNMEW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VNMEW's ROE of +18.81%. Regarding short-term risk, DMII is less volatile compared to VNMEW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VNMEW's competition here
Meridian3 Industrials Aquisition Corp Warrant (NASDAQ: MIACW)
DMII vs MIACW Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, MIACW has a market cap of 208.8M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while MIACW trades at $0.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas MIACW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MIACW's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to MIACW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check MIACW's competition here
Safeguard Acquisition Corp. (NYSE: SAC-UN)
DMII vs SAC-UN Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, SAC-UN has a market cap of 208M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while SAC-UN trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas SAC-UN's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SAC-UN's ROE of +0.00%. Regarding short-term risk, DMII is more volatile compared to SAC-UN. This indicates higher risk in terms of short-term price fluctuations for DMII.Check SAC-UN's competition here
TRG Latin America Acquisitions Corp. Class A Ordinary Shares (NASDAQ: TRGS)
DMII vs TRGS Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, TRGS has a market cap of 207.9M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while TRGS trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas TRGS's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TRGS's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to TRGS. This indicates lower risk in terms of short-term price fluctuations for DMII.Check TRGS's competition here
Jones Ventures Intl Acquisition1 (NASDAQ: JONE)
DMII vs JONE Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, JONE has a market cap of 206.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while JONE trades at $9.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas JONE's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to JONE's ROE of +7.88%. Regarding short-term risk, DMII is more volatile compared to JONE. This indicates higher risk in terms of short-term price fluctuations for DMII.Check JONE's competition here
Vendome Acquisition Corporation I Unit (NASDAQ: VNMEU)
DMII vs VNMEU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, VNMEU has a market cap of 206M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while VNMEU trades at $10.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas VNMEU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VNMEU's ROE of +18.81%. Regarding short-term risk, DMII is more volatile compared to VNMEU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check VNMEU's competition here
Vendome Acquisition Corporation I (NASDAQ: VNME)
DMII vs VNME Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, VNME has a market cap of 205.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while VNME trades at $10.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas VNME's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to VNME's ROE of +18.81%. Regarding short-term risk, DMII is less volatile compared to VNME. This indicates lower risk in terms of short-term price fluctuations for DMII.Check VNME's competition here
Karman Line Acquisition Corp. Units (NASDAQ: XTERU)
DMII vs XTERU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, XTERU has a market cap of 204.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while XTERU trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas XTERU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to XTERU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to XTERU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check XTERU's competition here
Interprivate Investment Partners V Inc. (NASDAQ: IPVV)
DMII vs IPVV Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, IPVV has a market cap of 204.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while IPVV trades at $9.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas IPVV's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to IPVV's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to IPVV. This indicates lower risk in terms of short-term price fluctuations for DMII.Check IPVV's competition here
Karman Line Acquisition Corp. (NASDAQ: XTER)
DMII vs XTER Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, XTER has a market cap of 202.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while XTER trades at $9.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas XTER's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to XTER's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to XTER. This indicates similar risk in terms of short-term price fluctuations for DMII.Check XTER's competition here
QDRO Acquisition Corp. Class A Ordinary Shares (NASDAQ: QADR)
DMII vs QADR Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, QADR has a market cap of 199.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while QADR trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas QADR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to QADR's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to QADR. This indicates lower risk in terms of short-term price fluctuations for DMII.Check QADR's competition here
QDRO Acquisition Corp. Units (NASDAQ: QADRU)
DMII vs QADRU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, QADRU has a market cap of 199.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while QADRU trades at $10.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas QADRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to QADRU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to QADRU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check QADRU's competition here
Meridian3 Ind S Acquisition Corp. (NASDAQ: MIAC)
DMII vs MIAC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, MIAC has a market cap of 197.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while MIAC trades at $9.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas MIAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MIAC's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to MIAC. This indicates higher risk in terms of short-term price fluctuations for DMII.Check MIAC's competition here
Oceanhawk Acquisition Corp. Class A Ordinary Shares (NASDAQ: OHAC)
DMII vs OHAC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, OHAC has a market cap of 188.9M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while OHAC trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas OHAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to OHAC's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to OHAC. This indicates similar risk in terms of short-term price fluctuations for DMII.Check OHAC's competition here
Enhanced Group Inc. Class A (NYSE: ENHA)
DMII vs ENHA Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, ENHA has a market cap of 186.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while ENHA trades at $1.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas ENHA's P/E ratio is -5.37. In terms of profitability, DMII's ROE is +0.03%, compared to ENHA's ROE of -0.86%. Regarding short-term risk, DMII is less volatile compared to ENHA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ENHA's competition here
JAB Acquisition Corp. I Class A (NASDAQ: ATLQ)
DMII vs ATLQ Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, ATLQ has a market cap of 185.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while ATLQ trades at $9.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas ATLQ's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ATLQ's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to ATLQ. This indicates lower risk in terms of short-term price fluctuations for DMII.Check ATLQ's competition here
Dynamix Corp (NASDAQ: ETHM)
DMII vs ETHM Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, ETHM has a market cap of 180.7M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while ETHM trades at $10.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas ETHM's P/E ratio is -13.61. In terms of profitability, DMII's ROE is +0.03%, compared to ETHM's ROE of +0.62%. Regarding short-term risk, DMII is more volatile compared to ETHM. This indicates higher risk in terms of short-term price fluctuations for DMII.Check ETHM's competition here
Social Commerce Partners Corporation (NASDAQ: SCPQW)
DMII vs SCPQW Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, SCPQW has a market cap of 180.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while SCPQW trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas SCPQW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SCPQW's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to SCPQW. This indicates higher risk in terms of short-term price fluctuations for DMII.Check SCPQW's competition here
Roman DBDR Acquisition Corp. II (NASDAQ: DRDBW)
DMII vs DRDBW Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, DRDBW has a market cap of 179.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while DRDBW trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas DRDBW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to DRDBW's ROE of +0.02%. Regarding short-term risk, DMII is less volatile compared to DRDBW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check DRDBW's competition here
JAB Acquisition Corp. I Units Cons of 1 Sh -A- + 1 Red Wt + 1 Rt (NASDAQ: ATLQU)
DMII vs ATLQU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, ATLQU has a market cap of 177.7M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while ATLQU trades at $10.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas ATLQU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to ATLQU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to ATLQU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check ATLQU's competition here
Long Table Growth Corp. Units (NASDAQ: LTGRU)
DMII vs LTGRU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, LTGRU has a market cap of 175.8M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while LTGRU trades at $10.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas LTGRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LTGRU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to LTGRU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check LTGRU's competition here
Jab Acquisition Corp. I (NASDAQ: JAB)
DMII vs JAB Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, JAB has a market cap of 174.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while JAB trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas JAB's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to JAB's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to JAB. This indicates lower risk in terms of short-term price fluctuations for DMII.Check JAB's competition here
Long Table Growth Corp. (NASDAQ: LTGR)
DMII vs LTGR Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, LTGR has a market cap of 171.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while LTGR trades at $9.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas LTGR's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to LTGR's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to LTGR. This indicates higher risk in terms of short-term price fluctuations for DMII.Check LTGR's competition here
Paloma Acquisition Corp I Class A Ordinary Shares (NASDAQ: PALO)
DMII vs PALO Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, PALO has a market cap of 169.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while PALO trades at $9.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas PALO's P/E ratio is -3216.13. In terms of profitability, DMII's ROE is +0.03%, compared to PALO's ROE of +0.00%. Regarding short-term risk, DMII is less volatile compared to PALO. This indicates lower risk in terms of short-term price fluctuations for DMII.Check PALO's competition here
Social Capital Hedosophia Holdings Corp. IV (NASDAQ: IPOD)
DMII vs IPOD Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, IPOD has a market cap of 155M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while IPOD trades at $10.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas IPOD's P/E ratio is 41.15. In terms of profitability, DMII's ROE is +0.03%, compared to IPOD's ROE of +0.05%. Regarding short-term risk, DMII is less volatile compared to IPOD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check IPOD's competition here
Graf Global Corp. (AMEX: TONT)
DMII vs TONT Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, TONT has a market cap of 154.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while TONT trades at $10.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas TONT's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TONT's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to TONT. This indicates higher risk in terms of short-term price fluctuations for DMII.Check TONT's competition here
Black Spade Acquisition II Co (NASDAQ: BSIIU)
DMII vs BSIIU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, BSIIU has a market cap of 152.8M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while BSIIU trades at $9.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas BSIIU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to BSIIU's ROE of -266.79%. Regarding short-term risk, DMII is more volatile compared to BSIIU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check BSIIU's competition here
JAB Acquisition Corp I (NASDAQ: JABRU)
DMII vs JABRU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, JABRU has a market cap of 152.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while JABRU trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas JABRU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to JABRU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to JABRU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check JABRU's competition here
Collective Acquisition Corp. (NASDAQ: CCAQ)
DMII vs CCAQ Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, CCAQ has a market cap of 151.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while CCAQ trades at $10.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas CCAQ's P/E ratio is 40.27. In terms of profitability, DMII's ROE is +0.03%, compared to CCAQ's ROE of +0.03%. Regarding short-term risk, DMII is less volatile compared to CCAQ. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CCAQ's competition here
Collective Acquisition Corp. (NASDAQ: CCAQU)
DMII vs CCAQU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, CCAQU has a market cap of 149.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while CCAQU trades at $10.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas CCAQU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CCAQU's ROE of +0.03%. Regarding short-term risk, DMII is more volatile compared to CCAQU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check CCAQU's competition here
Breeze Acquisition Corp. II (NASDAQ: BREZR)
DMII vs BREZR Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, BREZR has a market cap of 149.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while BREZR trades at $0.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas BREZR's P/E ratio is -28.00. In terms of profitability, DMII's ROE is +0.03%, compared to BREZR's ROE of +0.53%. Regarding short-term risk, DMII is more volatile compared to BREZR. This indicates higher risk in terms of short-term price fluctuations for DMII.Check BREZR's competition here
Southern Cross Acquisition I Corp. (NASDAQ: NCO)
DMII vs NCO Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, NCO has a market cap of 146M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while NCO trades at $9.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas NCO's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NCO's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to NCO. This indicates similar risk in terms of short-term price fluctuations for DMII.Check NCO's competition here
Breeze Acquisition Corp. II (NASDAQ: BREZ)
DMII vs BREZ Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, BREZ has a market cap of 144.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while BREZ trades at $10.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas BREZ's P/E ratio is -1001.00. In terms of profitability, DMII's ROE is +0.03%, compared to BREZ's ROE of +0.53%. Regarding short-term risk, DMII is more volatile compared to BREZ. This indicates higher risk in terms of short-term price fluctuations for DMII.Check BREZ's competition here
Three Lions Acquisition Corp. Units (NASDAQ: TLACU)
DMII vs TLACU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, TLACU has a market cap of 139.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while TLACU trades at $9.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas TLACU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to TLACU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to TLACU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check TLACU's competition here
Forefront Tech Holdings Acquisition Corp Unit (NASDAQ: FTHAU)
DMII vs FTHAU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, FTHAU has a market cap of 138.1M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while FTHAU trades at $10.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas FTHAU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to FTHAU's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to FTHAU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check FTHAU's competition here
Ocean Capital Acquisition Corporation (NYSE: OCAC)
DMII vs OCAC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, OCAC has a market cap of 136M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while OCAC trades at $9.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas OCAC's P/E ratio is -689.98. In terms of profitability, DMII's ROE is +0.03%, compared to OCAC's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to OCAC. This indicates higher risk in terms of short-term price fluctuations for DMII.Check OCAC's competition here
East West Ave Acquisition Corp. Common Stock (NASDAQ: EWAV)
DMII vs EWAV Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, EWAV has a market cap of 130.9M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while EWAV trades at $9.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas EWAV's P/E ratio is -14142.86. In terms of profitability, DMII's ROE is +0.03%, compared to EWAV's ROE of N/A. Regarding short-term risk, DMII is more volatile compared to EWAV. This indicates higher risk in terms of short-term price fluctuations for DMII.Check EWAV's competition here
Southern Cross Acquisition I Corp. (NASDAQ: NCOOU)
DMII vs NCOOU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, NCOOU has a market cap of 130.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while NCOOU trades at $10.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas NCOOU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to NCOOU's ROE of N/A. Regarding short-term risk, DMII is similarly volatile compared to NCOOU. This indicates similar risk in terms of short-term price fluctuations for DMII.Check NCOOU's competition here
Futurewave Acquisition Corp. (NASDAQ: FWAC)
DMII vs FWAC Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, FWAC has a market cap of 127.6M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while FWAC trades at $9.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas FWAC's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to FWAC's ROE of -0.17%. Regarding short-term risk, DMII is more volatile compared to FWAC. This indicates higher risk in terms of short-term price fluctuations for DMII.Check FWAC's competition here
Shepherd Ave Capital Acquisition Corporation (NASDAQ: SPHA)
DMII vs SPHA Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, SPHA has a market cap of 111.7M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while SPHA trades at $10.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas SPHA's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SPHA's ROE of -1.30%. Regarding short-term risk, DMII is less volatile compared to SPHA. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SPHA's competition here
Collective Acquisition Corp. (NASDAQ: CCAQW)
DMII vs CCAQW Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, CCAQW has a market cap of 107.2M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while CCAQW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas CCAQW's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CCAQW's ROE of +0.03%. Regarding short-term risk, DMII is less volatile compared to CCAQW. This indicates lower risk in terms of short-term price fluctuations for DMII.Check CCAQW's competition here
Amanat Acquisition Corp Class A Ordinary Shares (NASDAQ: AMAN)
DMII vs AMAN Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, AMAN has a market cap of 103.7M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while AMAN trades at $10.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas AMAN's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to AMAN's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to AMAN. This indicates lower risk in terms of short-term price fluctuations for DMII.Check AMAN's competition here
Southern Cross Acquisition II Corp. (NASDAQ: SCATU)
DMII vs SCATU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, SCATU has a market cap of 102.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while SCATU trades at $10.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas SCATU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to SCATU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to SCATU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check SCATU's competition here
Cayson Acquisition Corp (NASDAQ: CAPNU)
DMII vs CAPNU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, CAPNU has a market cap of 94M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while CAPNU trades at $11.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas CAPNU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to CAPNU's ROE of +0.03%. Regarding short-term risk, DMII is more volatile compared to CAPNU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check CAPNU's competition here
Research Alliance Corp. Iv (NASDAQ: RACD)
DMII vs RACD Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, RACD has a market cap of 90.3M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while RACD trades at $11.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas RACD's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to RACD's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to RACD. This indicates lower risk in terms of short-term price fluctuations for DMII.Check RACD's competition here
Miluna Acquisition Corp Class A Ordinary Share (NASDAQ: MMTX)
DMII vs MMTX Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, MMTX has a market cap of 89.9M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while MMTX trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas MMTX's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to MMTX's ROE of +0.07%. Regarding short-term risk, DMII is more volatile compared to MMTX. This indicates higher risk in terms of short-term price fluctuations for DMII.Check MMTX's competition here
Peace Acquisition Corp Units (NASDAQ: PECEU)
DMII vs PECEU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, PECEU has a market cap of 87.8M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while PECEU trades at $10.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas PECEU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to PECEU's ROE of N/A. Regarding short-term risk, DMII is less volatile compared to PECEU. This indicates lower risk in terms of short-term price fluctuations for DMII.Check PECEU's competition here
YHN Acquisition I Limited Unit (NASDAQ: YHNAU)
DMII vs YHNAU Comparison September 2026
Drugs Made In America Acquisition II Corp. Ordinary Shares (NASDAQ: DMII) plays a significant role within the Financial Services sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, DMII stands at 648.5M. In comparison, YHNAU has a market cap of 87.4M. Regarding current trading prices, DMII is priced at $10.17 on the NASDAQ, while YHNAU trades at $11.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
DMII currently has a P/E ratio of 72.71, whereas YHNAU's P/E ratio is N/A. In terms of profitability, DMII's ROE is +0.03%, compared to YHNAU's ROE of +0.10%. Regarding short-term risk, DMII is more volatile compared to YHNAU. This indicates higher risk in terms of short-term price fluctuations for DMII.Check YHNAU's competition here